AU2023902805A0 - Combination for use in the treatment of glioma - Google Patents

Combination for use in the treatment of glioma

Info

Publication number
AU2023902805A0
AU2023902805A0 AU2023902805A AU2023902805A AU2023902805A0 AU 2023902805 A0 AU2023902805 A0 AU 2023902805A0 AU 2023902805 A AU2023902805 A AU 2023902805A AU 2023902805 A AU2023902805 A AU 2023902805A AU 2023902805 A0 AU2023902805 A0 AU 2023902805A0
Authority
AU
Australia
Prior art keywords
glioma
treatment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023902805A
Inventor
John Bickerdike Michael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antido Therapeutics International Sarl
Original Assignee
Antido Therapeutics International Sarl
Filing date
Publication date
Application filed by Antido Therapeutics International Sarl filed Critical Antido Therapeutics International Sarl
Publication of AU2023902805A0 publication Critical patent/AU2023902805A0/en
Pending legal-status Critical Current

Links

AU2023902805A 2023-08-31 Combination for use in the treatment of glioma Pending AU2023902805A0 (en)

Publications (1)

Publication Number Publication Date
AU2023902805A0 true AU2023902805A0 (en) 2023-09-14

Family

ID=

Similar Documents

Publication Publication Date Title
EP4295846A3 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
EP4066837A4 (en) Use of bi853520 in cancer treatment
RS64486B1 (en) Deuterated compounds for use in the treatment of cancer
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB201918410D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918414D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918413D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
EP3917571A4 (en) Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
AU2023902805A0 (en) Combination for use in the treatment of glioma
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL309172A (en) Valbenazine for use in the add-on treatment of schizophrenia
IL308058A (en) Molephantin derivatives useful in the treatment of cancer
IL282718A (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
EP4025258A4 (en) Methods and compositions for the treatment of als
EP3804722A4 (en) Treatment agent and pharmaceutical composition for glioma
PL3937949T3 (en) Phytoecdysones and the derivatives thereof for use in the treatment of impaired lung function
EP4028395A4 (en) Sulfonamide compounds and the use thereof in the treatment of cancer
AU2019903886A0 (en) Sulfonamide compounds and the use thereof in the treatment of cancer
GB202302121D0 (en) Compounds for use in the treatment of schizophrenia
GB201918416D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB202014589D0 (en) Agents for use in the treatment of amyloidosis
AU2019900258A0 (en) Pyran compounds and their use in the treatment of pain
AU2021903239A0 (en) Agents and methods for therapy and prophylaxis
AU2021900345A0 (en) Agents and methods for therapy and prophylaxis
EP3989953A4 (en) A composition of cannabidiol for use in the treatment and prevention of bronchiolitis obliterans